Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
NEW YORK — Four agencies are contending in an estimated $100 million creative review for a new prescription drug from Novartis, sources said.
The drug, with the working names “Zelmac” and “Zelnorm,” is for the treatment of irritable bowel syndrome. Its generic name is “tegaserod.”
Sources said the four New York-based finalists are Interpublic Group’s McCann-Erickson and Deutsch; Cline, Davis & Mann, a healthcare agency owned by Omnicom; and WPP Group’s Ogilvy & Mather. Ogilvy sister shop MindShare, New York, handles Novartis media.
Sources
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in